The role of iron in diabetes and its complications

Diabetes Care

Volumn 30, Issue 7, 2007, Pages 1926-1933

  Swaminathan, Sundararaman ^a,c   Fonseca, Vivian A ^b   Alam, Muhammad G ^a   Shah, Sudhir V ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE;

BETA THALASSEMIA; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; HUMAN; INSULIN RESISTANCE; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; IRON STORAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; IRON; IRON OVERLOAD; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 34447132110     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2625     Document Type: Review

References (115)

1. Halliwell B, Gutteridge JMC: Role of free radicals and catalytic metal ions in human disease: an overview. Meth Enzymol 186:1-85, 1990
2. Fridovich I: The biology of oxygen radicals. Science 201:875-880, 1978
3. Jiang R, Ma J, Ascherio A, Stampfer MJ, Willett WC, Hu FB: Dietary iron intake and blood donations in relation to risk of type 2 diabetes in men: a prospective cohort study. Am J Clin Nutr 79:70-75, 2004
4. Fernandez-Real JM, Lopez-Bermejo A, Ricart W: Iron stores, blood donation, and insulin sensitivity and secretion. Clin Chem 51:1201-1205, 2005
5. Cooksey RC, Jouihan HA, Ajioka RS, Hazel MW, Jones DL, Kushner JP, McClain DA: Oxidative stress, beta-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis. Endocrinology 145:5305-5312, 2004
6. Tiedge M, Lortz S, Drinkgern J, Lenzen S: Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46:1733-1742, 1997
7. Andrews NC: The iron transporter DMT 1. Int J Biochem Cell Biol 31:991-994, 1999
8. Merkel PA, Simonson DC, Amiel SA, Plewe G, Sherwin RS, Pearson HA, Tamborlane WV: Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 318:809-814, 1988
9. Cario H, Holl RW, Debatin KM, Kohne E: Insulin sensitivity and beta-cell secretion in thalassaemia major with secondary haemochromatosis: assessment by oral glucose tolerance test. Eur J Pediatr 162:139-146, 2003
10. McClain DA, Abraham D, Rogers J, Brady R, Gault P, Ajioka R, Kushner JP: High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia 49:1661-1669, 2006
11. Dandona P, Hussain MA, Varghese Z, Politis D, Flynn DM, Hoffbrand AV: Insulin resistance and iron overload. Ann Clin Biochem 20:77-79, 1983
12. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, Le Gall JY, Brissot P, David V, Deugnier Y: Insulin resistance-associated hepatic iron overload. Gastroenterology 117:1155-1163, 1999
13. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, Acton RA, Harris EL, Gordeuk VR, Leiendecker-Foster C, Speechley M, Snively BM, Holup JL, Thomson E, Sholinsky P, Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators: Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 352:1769-1778, 2005
14. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA: Practice guideline development task force of the College of American Pathologists: hereditary hemochromatosis. Clin Chim Acta 245:139-200, 1996
15. Dymock IW, Cassar J, Pyke DA, Oakley WG, Williams R: Observations on the pathogenesis, complications and treatment of diabetes in 115 cases of haemochromatosis. Am J Med 52:203-210, 1972
16. Inoue Y, Nakanishi K, Hiraga T, Okubo M, Murase T, Kosaka K, Miyakoshi S, Mutoh Y, Kobayashi T: Recovery of pancreatic beta-cell function in hemochromatosis: combined treatment with recombinant human erythropoietin and phlebotomy. Am J Med Sci 314:6, 1997
17. Njajou OT, Vaessen N, Oostra B, Heutink P, Van Duijn CM: The hemochromatosis N144H mutation of SLC11A3 gene in patients with type 2 diabetes. Mol Genet Metab 75:290-291, 2002
18. Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, Dube MP, Andres L, MacFarlane J, Sakellaropoulos N, Politou M, Nemeth E, Thompson J, Risler JK, Zaborowska C, Babakaiff R, Radomski CC, Pape TD, Davidas O, Christakis J, Brissot P, Lockitch G, Ganz T, Hayden MR, Goldberg YP: Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 36:77-82, 2004
19. Miyajima H: Aceruloplasminemia, an iron metabolic disorder. Neuropathology 23:345-350, 2003
20. Miyajima H, Kono S, Takahashi Y, Sugimoto M: Increased lipid peroxidation and mitochondrial dysfunction in aceruloplasminemia brains. Blood Cells Mol Dis 29:433-438, 2002
21. Vantyghem M-C, Fajardy I, Dhondt F, Girardot C, Herbomez MD, Danze P-M, Rousseaux J, Wemeau J-L: Phenotype and HFE genotype in a population with abnormal iron markers recruited from an Endocrinology Department. Eur J Endocrinol 154:835-841, 2006
22. Acton RT, Barton JC, Passmore LV, Adams PC, Speechley MR, Dawkins FW, Sholinsky P, Reboussin DM, McLaren GD, Harris EL, Bent TC, Vogt TM, Castro O: Relationships of serum ferritin, transferrin saturation, and HFE mutations and self-reported diabetes in the hemochromatosis and iron overload screening (HEIRS) study. Diabetes Care 29:2084-2089, 2006
23. Fumeron F, Péan F, Driss F, Balkau B, Tichet J, Marre M, Grandchamp B: Ferritin and transferrin are both predictive of the onset of hyperglycemia in men and women over 3 years: the data from an epidemiological study on the insulin resistance syndrome (DESIR) study. Diabetes Care 29:2090-2094, 2006
24. Chern JPS, Lin K-H, Lu M-Y, Lin D-T, Lin K-S, Chen J-D, Fu C-C: Abnormal glucose tolerance in transfusion-dependent β-thalassemic patients. Diabetes Care 24:850-854, 2001
25. Papanikolaou G, Pantopoulos K: Iron metabolism and toxicity. Toxicol Appl Pharmacol 202:199-211, 2005
26. Cavallo-Perin P, Pacini G, Cerutti F, Bessone A, Condo C, Sacchetti L, Piga A, Pagano G: Insulin resistance and hyperinsulinemia in homozygous beta-thalassemia. Metabolism 44:281-286, 1995
27. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331:567-573, 1994
28. Platis O, Anagnostopoulos G, Farmaki K, Posantzis M, Gotsis E, Tolis G: Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy. Pediatr Endocrinol Rev 2:279-281, 2004
29. Loebstein R, Lehotay DC, Luo X, Bartfay W, Tyler B, Sher GD: Diabetic nephropathy in hypertransfused patients with β-thalassemia: the role of oxidative stress. Diabetes Care 21:1306-1309, 1998
30. Walker ARP, Segal I: Iron overload in Sub-Saharan Africa: to what extent is it a public health problem? Br J Nutr 81:427-434, 1999
31. Gordeuk VR, McLaren CE, Looker AC, Hasselblad V, Brittenham GM: Distribution of transferrin saturations in the African-American population. Blood 91:2175-2179, 1998
32. Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF: Potential role of increased iron stores in diabetes. Am J Med Sci 325:332-339, 2003
33. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133:592-599, 2000
34. Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, Ferrannini E: Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care 28:2548-2550, 2005
35. Franks AGJ, Pulini M, Bickers DR, Rayfield EJ, Harber LC: Carbohydrate metabolism in porphyria cutanea tarda. Am J Med Sci 277:163-171, 1979
36. Soma J, Saito T, Taguma Y, Chiba S, Sato H, Sugimura K, Ogawa S, Ito S: High prevalence and adverse effect of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol 11:690-699, 2000
37. Arber N, Konikoff FM, Moshkowitz M, Baratz M, Hallak A, Santo M, Halpern Z, Weiss H, Gilat T: Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci 39:2656-2659, 1994
38. Boujaoude L, Baker S, Baker R: Iron and hepatitis C. J Pediatr Gastroenterol Nutr 31:91-92, 2000
39. Ristow M, Giannakidou E, Hebinck J, Busch K, Vorgerd M, Kotzka J, Knebel B, Mueller-Berghaus J, Epplen C, Pfeiffer A, Kahn CR, Doria A, Krone W, Mueller-Wieland D: An association between NIDDM and a GAA trinucleotide repeat polymorphism in the X25/frataxin (Friedreich's ataxia) gene. Diabetes 47:851-854, 1998
40. Ristow M, Mulder H, Pomplun D, Schulz TJ, Muller-Schmehl K, Krause A, Fex M, Puccio H, Muller J, Isken F, Spranger J, Muller-Wieland D, Magnuson MA, Mohlig M, Koenig M, Pfeiffer AF: Frataxin deficiency in pancreatic islets causes diabetes due to loss of beta cell mass. J Clin Invest 112:527-534, 2003
41. Karthikeyan G, Santos JH, Graziewicz MD, Copeland WC, Isaya G, Van Houten B, FAR: Reduction in frataxin causes progressive accumulation of mitochondrial damage. Hum Mol Genet 12:3331-3342, 2003
42. Strom TM, Hortnagel K, Hofmann S, Gekeler F, Scharfe C, Rabl W, Gerbitz KD, Meitinger T: Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein. Hum Mol Genet 7:2021-2028, 1998
43. Ozdemir MA, Akcakus M, Kurtoglu S, Gunes T, Torun YA: TRMA syndrome (thiamine-responsive megaloblastic anemia): a case report and review of the literature. Pediatr Diabetes 3:205-209, 2002
44. Alcolado JC, Laji K, Gill-Randall R: Maternal transmission of diabetes. Diabet Med 19:89-98, 2002
45. Ponka P: Cellular iron metabolism. Kidney Int Suppl 69:S2-S11, 1999
46. Ford ES, Cogswell ME: Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 22:1978-1983, 1999
47. Snowdon DA, Phillips RL: Does a vegetarian diet reduce the occurrence of diabetes? Am J Public Health 75:507-512, 1985
48. Schulze MB, Manson JE, Willett WC, Hu FB: Processed meat intake and incidence of type 2 diabetes in younger and middle-aged women. Diabetologia 46:1465-1473, 2003
49. van Dam RM, Willett WC, Rimm EB, Stampfer MJ, Hu FB: Dietary fat and meat intake in relation to risk of type 2 diabetes in men. Diabetes Care 25:417-424, 2002
50. Song Y, Manson JE, Buring JE, Liu S: A prospective study of red meat consumption and type 2 diabetes in middle-aged and elderly women: the women's health study. Diabetes Care 27:2108-2115, 2004
51. Lee DH, Folsom AR, Jacobs DRJ: Dietary iron intake and type 2 diabetes incidence in postmenopausal women: the Iowa Women's Health Study. Diabetologia 47:185-194, 2004
52. Rajpathak S, Ma J, Manson J, Willett WC, Hu FB: Iron intake and the risk of type 2 diabetes in women: a prospective cohort study. Diabetes Care 29:1370-1376, 2006
53. Sheu WH, Chen YT, Lee WJ, Wang CW, Lin LY: A relationship between serum ferritin and the insulin resistance syndrome is present in non-diabetic women but not in non-diabetic men. Clin Endocrinol (Oxf) 58:380-385, 2003
54. Tuomainen TP, Nyyssonen K, Salonen R, Tervahauta A, Korpela H, Lakka T, Kaplan GA, Salonen JT: Body iron stores are associated with serum insulin and blood glucose concentrations: population study in 1,013 eastern Finnish men. Diabetes Care 20:426-428, 1997
55. Jehn MCJ, Guallar E: Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 27:2422-2428, 2004
56. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W: Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and β-cell function. Diabetes 51:1000-1004, 2002
57. Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G, Tenuti I, Lotto V, Friso S, Pizzolo F, Corrocher R: Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 28:2061-2063, 2005
58. Lao TT, Tam KF: Maternal serum ferritin and gestational impaired glucose tolerance. Diabetes Care 20:1368-1369, 1997
59. Chen X, Scholl TO, Stein TP: Association of elevated serum ferritin levels and the risk of gestational diabetes mellitus in pregnant women: the Camden study. Diabetes Care 29:1077-1082, 2006
60. Jiang R, Manson JA, Meigs JB, Ma J, Rifai N, Hu FB: Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. J Am Med Assoc 291:711-717, 2004
61. Jehn ML, Guallar E, Clark JM, Couper D, Duncan BB, Ballantyne CM, Hoogeveen RC, Harris ZL, Pankow JS: A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 165:1047-1054, 2007
62. Lee DH, Liu DY, Jacobs DRJ, Shin HR, Song K, Lee IK, Kim B, Hider RC: Common presence of non-transferrin-bound iron among patients with type 2 diabetes. Diabetes Care 29:1090-1095, 2006
63. Bofill C, Joven J, Bages J, Vilella E, Sans T, Cavalle P, Miralles R, Llobet J, Camps J: Response to repeated phlebotomies in patients with non-insulin-dependent diabetes mellitus. Metabolism 43:614-620, 1994
64. Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, Bunn HF: Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 304:319-324, 1981
65. Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B: Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab 77:478-483, 1993
66. Ascherio A, Rimm EB, Giovannucci EL, Willett WC, Stampfer MJ: Blood donations and risk of coronary heart disease in men. Circulation 103:52-57, 2001
67. Facchini FS, Saylor KL: A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes 52:1204-1209, 2003
68. Lao TT, Ho LF: Impact of iron deficiency anemia on prevalence of gestational diabetes mellitus. Diabetes Care 27:650-656, 2004
69. Qian M, Liu M, Eaton JW: Transition metals bind to glycated proteins forming redox active "glycochelates:" implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Comm 250:385-389, 1998
70. Sullivan JL: Iron and the sex difference in heart disease risk. Lancet 1:1293-1294, 1981
71. Redmon JB, Pyzdrowski KL, Robertson RP: No effect of deferoxamine therapy on glucose homeostasis and insulin secretion in individuals with NIDDM and elevated serum ferritin. Diabetes 42:544-549, 1993
72. Young IS, Tate S, Lightbody JH, McMaster D, Trimble ER: The effect of ascorbate and desferrioxamine treatment on oxidative stress in the streptozotocin diabetic rat. Free Radic Biol Med 18:833-840, 1995
73. Nankivell BJ, Chen J, Boadle RA, Harris DCH: The role of tubular iron accumulation in the remnant kidney. J Am Soc Nephrol 4:1598-1607, 1994
74. Harris DC, Tay C, Nankivell BJ: Lysosomal iron accumulation and tubular damage in rat puromycin nephrosis and ageing. Clin Exp Pharmacol Physiol 21:73-81, 1994
75. Nankivell BJ, Boadle RA, Harris DCH: Iron accumulation in human chronic renal disease. Am J Kid Dis 20:580-584, 1992
76. Alfrey AC, Froment DH, Hammond WS: Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis. Kidney Int 36:753-759, 1989
77. Nath KA, Fischereder M, Hostetter TH: The role of oxidants in progressive renal injury. Kidney Int 45:S111-S115, 1994
78. Remuzzi A, Puntorieri S, Brugnetti B, Bertani T, Remuzzi G: Renoprotective effect of low iron diet and its consequence on glomerular hemodynamics. Kidney Int 39:647-652, 1991
79. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897, 1994
80. Hara T, Miyai H, Iida T, Futenma A, Nakamura S, Kato K: Aggravation of puromycin aminonucleoside (PAN) nephrosis by the inhibition of endogenous superoxide dismutase (SOD). In XI International Congress of Nephrology New York, Springer-Verlag, 1990, p. 442A
81. Ha H, Kim KH: Role of oxidative stress in the development of diabetic nephropathy. Kidney Int 48:S18-S21, 1995
82. Wohaieb SA, Godin DV: Alterations in free radical tissue-defense mechanisms in streptozocin-induced diabetes in rat: effects of insulin treatment. Diabetes 36:1014-1018, 1987
83. Howard RL, Buddington B, Alfrey AC: Urinary albumin, transferrin and iron excretion in diabetic patients. Kidney Intl 40:923-926, 1991
84. Johnson WT, Evans GW: Effects of the interrelationship between dietary protein and minerals on tissue content of trace metals in streptozotocin- diabetic rats. J Nutrit 114:180-190, 1984
85. Nishiya K, Takamatsu K, Yoshimoto Y, Ikeda Y, Ito H, Hashimoto K: Increased urinary iron excretion rate in patients with non-insulin dependent diabetes mellitus. Rinsho Byori 44:1201-1202, 1996
86. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A: Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood 107:3733-3737, 2006
87. Fabio G, Minonzio F, Delbini P, Bianchi A, Cappellini MD: Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by severe type of juvenile hemochromatosis (JH). Blood 109:362-364, 2007
88. Ascherio A, Willett WC, Rimm EB, Giovannucci EL, Stampfer MJ: Dietary iron intake and risk of coronary disease among men. Circulation 89:969-974, 1994
89. Lee DH, Folsom AR, Jacobs DRJ: Iron, zinc, and alcohol consumption and mortality from cardiovascular diseases: the Iowa Women's Health Study. Am J Clin Nutr 81:787-791, 2005
90. van der ADL, Peeters PH, Grobbee DE, Marx JJ, van der Schouw YT: Dietary haem iron and coronary heart disease in women. Eur Heart J 26:257-262, 2005
91. Ramakrishnan U, Kuklina E, Stein AD: Iron stores and cardiovascular disease risk factors in women of reproductive age in the United States. Am J Clin Nutr 76:1256-1260, 2002
92. Tuomainen T-P, Punnonen K, Nyyssönen K, Salonen JT: Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 97:1461-1466, 1998
93. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F: Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 96:3300-3307, 1997
94. Danesh J, Appleby P: Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation 99:852-854, 1999
95. Derstine JL, Murray-Kolb LE, Yu-Poth S, Hargrove RL, Kris-Etherton PM, Beard JL: Iron status in association with cardiovascular disease risk in 3 controlled feeding studies. Am J Clin Nutr 77:56-62, 2003
96. Baer DM, Tekawa IS, Hurley LB: Iron stores are not associated with acute myocardial infarction. Circulation 89:2915-2918, 1994
97. Corti MC, Guralnik JM, Salive ME, Ferrucci L, Pahor M, Wallace RB, Hennekens CH: Serum iron level, coronary artery disease, and all-cause mortality in older men and women. Am J Cardiol 79:120-127, 1997
98. Knuiman MW, Divitini ML, Olynyk JK, Cullen DJ, Bartholomew HC: Serum ferritin and cardiovascular disease: a 17-year follow-up study in Busselton, Western Australia. Am J Epidemiol 158:144-149, 2003
99. Sempos CT, Looker AC, Gillum RE, McGee DL, Vuong CV, Johnson CL: Serum ferritin and death from all causes and cardiovascular disease: the NHANES II Mortality Study. Ann Epidemiol 10:441-448, 2000
100. Gosriwatana I, Loreal O, Lu S, Brissot P, Porter J, Hider RC: Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem 273:212-220, 1999
101. Kartikasari AE, Georgiou NA, Visseren FL, van Kats-Renaud H, van Asbeck BS, Marx JJ: Intracellular labile iron modulates adhesion of human monocytes to human endothelial cells. Arterioscler Thromb Vasc Biol 24:2257-2262, 2004
102. Koo SW, Casper KA, Otto KB, Gira AK, Swerlick RA: Iron chelators inhibit VCAM-1 expression in human dermal microvascular endothelial cells. J Invest Dermatol 120:871-879, 2003
103. Zhang WJ, Frei B: Intracellular metal ion chelators inhibit TNFalpha-induced SP-1 activation and adhesion molecule expression in human aortic endothelial cells. Free Radic Biol Med 34:674-682, 2003
104. Agarwal R, Vasavada N, Sachs NG, Chase S: Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65:2279-2289, 2004
105. Day SM, Duquaine D, Mundada LV, Menon RG, Khan BV, Rajagopalan S, Fay WP: Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation 107:2601-2606, 2003
106. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:2212-2217, 2002
107. Zheng H, Huang X, Zhang Q, Katz SD: Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects. Kidney Int 69:679-684, 2006
108. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Lopez-Bermejo A, Ricart W: Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity. Diabetes Care 25:2249-2255, 2002
109. Salonen JT, Tuomainen TP, Salonen R, Lakka TA, Nyyssonen K: Donation of blood is associated with reduced risk of myocardial infarction: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Epidemiol 148:445-451, 1998
110. van der A DL, Marx JJ, Grobbee DE, Kamphuis MH, Georgiou NA, van Kats-Renaud JH, Breuer W, Cabantchik ZI, Roest M, Voorbij HA, van der SYT: Non-transferrin-bound iron and risk of coronary heart disease in postmenopausal women. Circulation 113:1942-1949, 2006
111. Cavill I: Intravenous iron as adjuvant therapy: a two-edged sword? Nephrol Dial Transplant 18 (Suppl. 8):viii24-viii28, 2003
112. MacCarthy PA, Grieve DJ, Li J-M, Dunster C, Kelly FJ, Shah AM: Impaired endothelial regulation of ventricular relaxation in cardiac hypertrophy: role of reactive oxygen species and NADPH oxidase. Circulation 104:2967-2974, 2001
113. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA: Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 50:1927-1937, 2001
114. Cameron NE, Cotter MA: Neurovascular dysfunction in diabetic rats. potential contribution of autoxidation and free radicals examined using transition metal chelating agents. J Clin Invest 96:1159-1163, 1995
115. Rund D, Rachmilewitz E: Beta-thalessemia. N Engl J Med 353:1135-1146, 2005